CTMX
CytomX Therapeutics, Inc.·Healthcare
4.39
0.000%(+0.00)
Close PriceLast Updated: — ET
52W L: $0.6152W H: $8.21
CTMX NEWS
defenseworld.net
Apr 5
CytomX Therapeutics (NASDAQ:CTMX) & Adagene (NASDAQ:ADAG) Financial Comparison
Adagene (NASDAQ: ADAG - Get Free Report) and CytomX Therapeutics (NASDAQ: CTMX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation. Analyst Recommendations This is a breakdown of current
defenseworld.net
Mar 31
Assenagon Asset Management S.A. Sells 137,271 Shares of CytomX Therapeutics, Inc. $CTMX
Assenagon Asset Management S.A. decreased its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX) by 18.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 592,696 shares of the biotechnology company's stock after selling 137,271 shares during the quarter. Assenagon Asset Management
defenseworld.net
Mar 20
CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) gapped up prior to trading on Thursday after Barclays raised their price target on the stock from $10.00 to $16.00. The stock had previously closed at $4.40, but opened at $4.51. Barclays currently has an overweight rating on the stock. CytomX Therapeutics shares last traded at $4.8370,
benzinga.com
Mar 18
Why Is CytomX Therapeutics Stock Falling On Wednesday?
On Tuesday, CytomX Therapeutics announced a public offering of 45.9 million shares at $5.30 per share, pre-funded warrants to purchase 1.179 million shares.
seekingalpha.com
Mar 18
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level
CytomX Therapeutics (CTMX) has generated significant excitement with strong early data for varsetatug masetecan in refractory colorectal cancer. Phase 1 results show 20–32% response rates and median PFS of 6.8–7.1 months, outperforming current treatments in this setting. CTMX is executing a $250 million equity raise, extending its cash runway and positioning for registrational studies, but remains pre-commercial.
globenewswire.com
Mar 17
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten public offering of 45,990,567 shares of its common stock at a price to the public of $5.30 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,179,245 shares of common stock. The gross proceeds to CytomX from the offering are expected to be $250 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, CytomX granted the underwriters a 30-day option to purchase up to an additional 7,075,471 shares of its common stock at the public offering price, less underwriting discounts and commissions. The closing of the offering is expected to occur on March 19, 2026, subject to customary closing conditions. All of the shares of common stock and pre-funded warrants are being sold by CytomX.
